Title :

Impact of in vivo T-cell depletion in patients with myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplant: a registry study from the Chronic Malignancies Working Party of the EBMT.

Author(s) :

Forcade, Edouard [Auteur]
Centre Hospitalier Universitaire de Bordeaux [CHU Bordeaux]
Chevret, Sylvie [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Finke, J. [Auteur]
Ehninger, G. [Auteur]
Ayuk, F. [Auteur]
Beelen, D. [Auteur]
Koster, L. [Auteur]
Ganser, A. [Auteur]
Volin, L. [Auteur]
Sengeloev, H. [Auteur]
Michallet, Mauricette [Auteur]
Tischer, J. [Auteur]
Jindra, P. [Auteur]
Cascon, M. J. P. [Auteur]
Koc, Y. [Auteur]
Arat, M. [Auteur]
Tomaszewska, A. [Auteur]
Hayden, P. [Auteur]
De Witte, T. [Auteur]
Yakoub-Agha, Ibrahim [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Kröger, N. [Auteur]
Robin, Marie [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]

Journal title :

Bone Marrow Transplantation

Abbreviated title :

Bone Marrow Transplant

Volume number :

57

Pages :

768–774

Publication date :

2022-03-02

ISSN :

1476-5365

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

While in vivo T-cell depletion (TCD) is widely used, its benefit in patients with MDS still remains a matter of debate. This study evaluates the impact of TCD on outcomes, and compares ATG and alemtuzumab, in patients with ...
Show more >While in vivo T-cell depletion (TCD) is widely used, its benefit in patients with MDS still remains a matter of debate. This study evaluates the impact of TCD on outcomes, and compares ATG and alemtuzumab, in patients with MDS. 1284 patients from the EBMT registry were included in this study with 470 patients in the no-TCD group and 814 in the TCD group (alemtuzumab N = 168; ATG N = 646). At 6 months, aGVHD III-IV cumulative incidences (CI) for no-TCD, ATG or alemtuzumab groups were 13% vs 14% vs 11% (ns), respectively. At 5 years, CI of chronic GVHD were 64% vs 52% vs 51% (p < 0.00017); and CI of relapse was 23% vs 25% vs 39% (p < 0.0001) for no TCD, ATG and alemtuzumab respectively; OS was 47% vs 46% vs 34% (p = 0.009) respectively; and GRFS was 21% vs 28% and 20% (p = 0.045) respectively. In multivariable analysis, ATG improved GRFS, and alemtuzumab decreased OS. Both ATG and alemtuzumab decreased risk of chronic GVHD, but the increased risk of relapse with alemtuzumab is associated with a poor GRFS and suggest to not use alemtuzumab in the setting of allo-SCT for high risk disease.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Submission date :

2024-01-12T02:11:41Z
2024-03-29T08:18:29Z